Skip to main content

Orthocell to up stake in ‘groundbreaking’ pearl bone substitute

53 min ago

Bookmark

Save articles for future reference.

Orthocell has entered an MOU to secure exclusive distribution rights for Marine Biomedical's innovative bone substitute PearlBone, and lift its stake in the company to 12 per cent.

X

To read our articles you will need to either login or subscribe.